On December 23, 2016, the US Food and Drug Administration (FDA) announced the approval of nusinersen, the first drug for the devastating disease spinal muscular atrophy. The approval was based on an interim analysis of 82 patients in a single randomized trial; 40% of treated children improved, compared with none in the control group. The FDA had requested that the interim analysis be conducted. A press release emphasized the speed of agency action, with the review division director saying, “We worked hard to review this application quickly.”1
Sharfstein JM. Reform at the FDA—In Need of Reform. JAMA. 2020;323(2):123–124. doi:10.1001/jama.2019.20538
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: